Effect of the m6ARNA gene on the prognosis of thyroid cancer, immune infiltration, and promising immunotherapy

Abstract

BackgroundAccumulating evidence suggests that N6-methyladenosine (m6A) RNA methylation plays an important role in tumor proliferation and growth. However, its effect on the clinical prognosis, immune infiltration, and immunotherapy response of thyroid cancer patients has not been investigated in detail.MethodsClinical data and RNA expression profiles of thyroid cancer were extracted from the Cancer Genome Atlas-thyroid carcinoma (TCGA-THCA) and preprocessed for consensus clustering. The risk model was constructed based on differentially expressed genes (DEGs) using Least Absolute Shrinkage and Selection Operator (LASSO) and Cox regression analyses. The associations between risk score and clinical traits, immune infiltration, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), immune infiltration, and immunotherapy were assessed. Immunohistochemistry was used to substantiate the clinical traits of our samples.ResultsGene expression analysis showed that 17 genes, except YHTDF2, had significant differences (vs healthy control, P<0.001). Consensus clustering yielded 2 clusters according to their clinical features and estimated a poorer prognosis for Cluster 1 (P=0.03). The heatmap between the 2 clusters showed differences in T (P<0.01), N (P<0.001) and stage (P<0.01). Based on univariate Cox and LASSO regression, a risk model consisting of three high-risk genes (KIAA1429, RBM15, FTO) was established, and the expression difference between normal and tumor tissues of three genes was confirmed by immunohistochemical results of our clinical tissues. KEGG and GSEA analyses showed that the risk DEGs were related mainly to proteolysis, immune response, and cancer pathways. The levels of immune infiltration in the high- and low-risk groups were different mainly in iDCs (P<0.05), NK cells (P<0.05), and type-INF-II (P<0.001). Immunotherapy analysis yielded 30 drugs associated with the expression of each gene and 20 drugs associated with the risk score.ConclusionsOur risk model can act as an independent marker for thyroid cancer and provides promising immunotherapy targets for its treatment.

Investigating Potential Drug Targets in Intracranial Aneurysms through Mendelian Randomization and Transcriptome Analyses

“…In the present study, we selected six independent NK cell and CD4 memory T cell summary level association results, including absolute NK cell count, NK cells/CD3-lymphocytes, NK/lymphocytes, HLA-DR+ NK AC, CD16-CD56+/NK cell. In this case, SNPs were filtered according to the procedure previously described [19]. Briefly, SNPs associated with relevant immune traits were extracted as IVs at the genome-wide significance level (P < 5.00E-6).…”

Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review

“…[19][20][21] It has also been widely applied in TC. [12,[22][23][24][25][26] With the wide application of immunotherapy in TC, a large number of related studies have emerged, accompanied by the publication of scientific papers. Bibliometrics is the application of mathematical and statistical methods to analyze data in relevant research fields.…”

The emerging roles of N6-methyladenosine RNA modifications in thyroid cancer

“…Particularly, the expression of HNRNPC is significantly elevated in TC, while WTAP, RBM15, YTHDC2, YTHDC1, FTO, METTL14, METTL3, ALKBH5, KIAA1429, YTHDF1, and ZC3H13 are remarkably decreased in tumor tissues; moreover, among these downregulated regulators, RBM15, KIAA1429, and FTO are used as a reference for prognostic analysis, which shows better performance in predicting the prognosis of TC with high accuracy [ 59 ]. This established m6A-related three-gene prognostic model is also independent prognostic markers of overall survival in TC, which modulate the key signaling pathways of TC progression, such as proteolysis and immune response [ 14 , 80 ]. It is also found that IGF2BP2, STT3A, MTHFD1, and GSTM4 could be a prognostic signature of TC patients to predict disease-free survival [ 74 ].…”